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0022-2836/© 2009 Elsevier Ltd. Open accStructural studies on G-protein-coupled receptors have been hampered for
many years by their instability in detergent solution and by the number of
potential conformations that receptors can adopt. Recently, the structures of
the β1 and β2 adrenergic receptors and the adenosine A2a receptor were
determined in the antagonist-bound state, a receptor conformation that is
thought to be more stable than the agonist-bound state. In contrast to these
receptors, the neurotensin (NT) receptor NTS1 is much less stable in
detergent solution. We have therefore used a systematic mutational
approach coupled with activity assays to identify receptor mutants suitable
for crystallization, both alone and in complex with the peptide agonist NT.
The best receptor mutant NTS1-7m contained four point mutations. It
showed increased stability compared to the wild-type receptor, in the
absence of ligand, after solubilization with a variety of detergents. In
addition, NTS1-7m bound to NT was more stable than unliganded NTS1-
7m. Of the four thermostabilizing mutations, only one residue (A86L) is
predicted to be in the lipid environment. In contrast, I260A appears to be
buried within the transmembrane helix bundle, F342A may form a distant
part of the putative ligand-binding site, whereas F358A is likely to be in a
region that is important for receptor activation. NTS1-7m binds NT with a
similar affinity for the wild-type receptor. However, agonist dissociation
was slower, and NTS1-7m activated G-proteins poorly. The affinity of
NTS1-7m for the antagonist SR48692 was also lower than that of the wild-
type receptor. Thus, we have successfully stabilized NTS1 in an agonist-
binding conformation that does not efficiently couple to G-proteins.© 2009 Elsevier Ltd. Open access under CC BY license.Keywords: membrane protein; G-protein-coupled receptor; conformational
thermostabilizationEdited by J. Bowieresses:
.cam.ac.uk.
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Determination ofmembrane protein structures has
long been regarded as a difficult area in structural
biology. To obtain diffraction-quality crystals, a
target membrane protein needs to be available in
sufficient quantities, stable in detergent solution
from which crystallization occurs, and obtainable
in one particular conformation. Stability in a range of
detergents is central to crystal formation, but other
factors such as removal of flexible protein parts or
choice of the crystallization system (vapor diffusion
or lipid-based approaches) may also need to be
considered.1 Increasing successes with bacterial
membrane proteins, such as transporters and ion
channels, have shown that many of the perceived
difficulties in membrane protein crystallization can
now be overcome. The first membrane protein struc-
263Thermostabilization of NTS1tures solved were all rigid, stable proteins and came
from natural sources: a photosynthetic reaction
center2 and an outermembrane porin3 from bacteria,
and the bovine cytochrome c oxidase4 and bc1
complex5 from mitochondria. More recently, eukar-
yotic membrane proteins from heterologously
expressed sources have also been crystallized (e.g.,
the rat Kv1.2 voltage-gated potassium channel
expressed in Pichia pastoris6 and a chicken acid-
sensing ion channel expressed in insect cells).7
One commonality between eukaryotic membrane
proteins, whose structures have been solved, may be
their relative stability in detergent—a consideration
that also applies to many prokaryotic membrane
proteins. Unfortunately, a direct comparison of the
stabilities of all membrane proteins in detergents in
which they have been crystallized has not been
carried out. However, many successful crystalliza-
tion conditions, especially for eukaryotic membrane
proteins, included ligands, lipids, and/or lipid-like
compounds, with the aim of improving the stability
of a particular membrane protein during crystal-
lization. If stability in detergent is one of the key
determinants of crystallizability, then solving struc-
tures of a large number of human membrane
proteins may currently not be possible because
solubilizing these proteins in detergent would
inactivate them.
Attempts to determine the structures of G-
protein-coupled receptors (GPCRs) have been
ongoing for over 20 years. Bovine rhodopsin was
the first GPCR to be crystallized,8–10 reflecting its
relatively high stability in many detergents as long
as the receptor was kept in its inactive, dark state.
Many other GPCRs have been overproduced in a
variety of expression systems,11 and some of them
have been purified to homogeneity. However, it has
only been recently that structures have been
determined for the human β2 adrenergic receptor
(β2AR)
12,13 and the human adenosine A2a receptor
(A2aR)
14 using the T4 lysozyme fusion strategy and
lipidic cubic-phase crystallization procedures, while
the structure of a thermostabilized β1 adrenergic
receptor (β1AR) was determined from crystals
grown in detergent by vapor diffusion.15 The
β2AR was also crystallized in complex with an
antibody fragment using the bicelle system.16 These
recent successes are due partly to increased usage of
microfocus beamlines to collect X-ray diffraction
data from very small crystals, but also due to our
understanding of how to maintain receptors in a
biologically relevant single conformation long
enough for crystallization to occur. This was
achieved by inclusion, during crystallization, of
high-affinity antagonists/inverse agonists (β2AR,
β1AR, and A2aR) or cholesteryl hemisuccinate
(CHS) (β2AR and A2aR), all of which are predicted
to improve the stability of the receptor during
crystallization.14,17–20 Receptor stability has also
been improved by site-directed mutagenesis
(β1AR), which allowed the use of more denaturing
short-chain detergents for crystallization.19 Insertion
of the T4 lysozyme fusion partner into the flexiblethird cytoplasmic loop of receptors appears to
improve the crystallizability of the receptor (β2AR
and A2aR),12,14 although the effect of T4 lysozyme
on the stability of the receptor is unknown.
We now know the structures of five GPCRs (β2AR,
β1AR, A2aR, bovine rhodopsin, and squid
rhodopsin21) in an inactive antagonist-bound state
and the structure of one GPCR (bovine opsin) in an
active-like state.22,23 Although the structures of
antagonist-bound GPCRs show great similarities
within transmembrane (TM) cores, there are also
differences, especially in the conformations of
extracellular and intracellular loops, such that it is
not yet possible to predict in atomic detail how, for
example, a specific ligand binds to a receptor of
unknown structure. β1AR, β2AR, and A2aR bind
small ligands within the TM core, and their
structures in the antagonist-bound states are similar
to the structure of dark-state rhodopsin. However,
larger ligands such as peptides involve receptor
regions other than the TM bundle for binding, and
agonist-bound receptors, regardless of the sizes of
their ligands, are thought to be much more flexible
and/or to undergo rapid equilibrium between
multiple structural states.24 Therefore, the agonist-
bound activated states of peptide receptors are still
an unknown territory in GPCR structures.
We have focused our attention on a peptide
receptor, the neurotensin (NT) receptor NTS1.25 NT
is a 13-amino-acid peptide agonist that is thought
to bind in an extended conformation26 to the
receptor at a site formed by both extracellular
loops and TM helices, as predicted from mutagen-
esis and structure–activity studies combined with
modeling techniques.27,28 The agonist-binding site
overlaps with that of the antagonist SR48692,
although the small synthetic antagonist requires
only the TM helices for its binding.29 Extensive
work on the expression and purification of NTS1
has led to the production of milligram quantities of
a highly purified functional receptor from Escher-
ichia coli,30 but diffraction-quality crystals have not
yet been obtained. NTS1 is not particularly stable in
detergent; it requires the presence of CHS and
glycerol throughout purification to retain ligand-
binding activity, and its stability in short-chain
detergents is severely compromised. We therefore
decided to identify thermostabilizing NTS1
mutants to allow the use of a wider range of
detergents and buffer conditions for crystallization.
Such a mutagenesis approach has successfully
identified mutations in both bacterial membrane
proteins31,32 and GPCRs,18,19 and conformational
thermostabilization of the β1AR in an antagonist-
bound form19 was essential for its subsequent
structure determination at 2.7 Å resolution.15 One
constraint that we imposed upon the stabilization
procedure was that NTS1 needed to be stabilized
ideally in both the unliganded state and the NT-
bound state because this would allow rapid
purification of the mutated receptor using a well-
established automated procedure.30 Here we
describe the successful thermostabilization of
Fig. 1. Thermal stability and expression levels of NTS1
single Ala/Leu mutants. (a) The thermal stability of wt-
NTS1 in the unliganded state (blue) and with NT bound
(red) was assessed by determining the apparent Tm value
from the midpoint of the curves. Apparent Tm of
unliganded wt-NTS1, 24±2 °C; apparent Tm of NT-
bound wt-NTS1, 37±2 °C. (b and c) Individual mutants
of NTS1, each containing a single alanine mutation (if the
original amino acid was alanine, then it was mutated to
leucine), are summarized for its expression level in E. coli
(number of functional receptors per cell), its thermal
stability in the absence of NT (b), and in the presence of
NT (c). Thermal stability was measured after incubating
each detergent-solubilized mutant at 24 °C (b) or 37 °C (c)
for 30 min, and the percentage of activity remaining after
incubation was determined with respect to its own
unheated control. All stability data are normalized against
wt-NTS1 stability for each set of experiments (wt=50%).
The mean wt-NTS1 expression level and stability (red dot)
and standard errors (red oval) are shown in the plots. The
dotted lines show the cutoff values for the stabilized
mutants (65% activity remaining, 250 receptors/cell).
264 Thermostabilization of NTS1NTS1 in both the unliganded state and the NT-
bound state.
Results
Development of thermostability assays for the
NT receptor
An essential prerequisite to our thermostabiliza-
tion strategy is to develop a robust thermostability
assay for the unpurified detergent-solubilized recep-
tor based upon radioligand binding.18,19 In this
instance, the thermostability of NTS1 was deter-
mined using a [3H]−neurotensin ([3H]-NT; [3,11-
tyrosyl-3,5-3H(N)]pyroGlu-Leu-Tyr-Glu-Asn-Lys-
Pro-Arg-Arg-Pro-Tyr-Ile-Leu) binding assay. To
directly compare the stability of wild-type neuro-
tensin receptor (wt-NTS1) with that of β1AR, wt-
NTS1 was solubilized, and its thermostability was
determined in a buffer system similar to that used
for β1AR, containing only n-dodecyl-β-D-maltopyr-
anoside (DDM).19 However, the apparent Tm in
DDM was rather low with limited reproducibility,
possibly because solubilized unliganded wt-
NTS1 was too unstable and therefore was sensitive
to fluctuations in laboratory temperature (results
not shown). To improve the reproducibility of
thermostability assays, 3-[(3-cholamidopyropyl)
dimethylammonio]-1-propanesulfonate (Chaps),
CHS, and glycerol at final concentrations of 0.6%,
0.12%, and 30%, respectively, were included during
the solubilization in 1% DDM, conditions that had
previously been found to be highly stabilizing.33 The
concentration of NaCl in the thermostability assay
was kept as low as possible (27 mM in the assay
buffer, carried over from the lysis buffer), as a
high concentration of Na+ is known to inhibit NT
binding to the receptor.34,35 The concentration of
[3H]-NT used in the assays (12 nM) was at least
fivefold above the apparent Kd value for detergent-
solubilized wt-NTS1 (Kd=1–2 nM in this buffer
condition; results not shown) to allow high receptor
occupancy, but it kept nonspecific [3H]-NT binding
to a minimum. Under these conditions, wt-NTS1
showed apparent Tm values of 24±2 °C in the un-
liganded state and 37±2 °C with NT bound (Fig. 1a).
The apparent Tm was defined as the temperature at
which 50% of the solubilized receptor remained
functional after incubation for 30 min.
In designing the thermostabilization strategy for
NTS1, we also considered how the receptor was
going to be purified and the most likely state in
which we would want to crystallize it. Crystal-
lization is best performed under conditions where
the receptor is most stable; NTS1 should therefore be
crystallized with NT bound, as suggested by the
thermostability assay (Fig. 1a). However, the pur-
ification scheme for NTS1 relies upon a ligand
affinity purification step using an NT-affinity
column.30 Therefore, the ideal NTS1 construct for
structural studies would be stable in both the
presence and the absence of NT. With this in mind,
Fig. 2. Schematic of the “+NT” and “−NT” thermostability assays.
265Thermostabilization of NTS1we developed two thermostability assay formats
for detergent-solubilized NTS1, which we refer to
as “−NT assay” and “+NT assay” (Fig. 2). In the
−NT assay, solubilized NTS1 was heated at
apparent Tm without a ligand (24 °C; Fig. 1a) for
30 min and placed on ice. [3H]-NT was then added
and, after a 1-h incubation on ice, the amount of
[3H]-NT bound to the receptor was determined by
using a mini gel-filtration spin column to separate
the receptor–ligand complex from free [3H]-NT. In
the +NT assay, the 30-min heating step at 37 °C
(apparent Tm with NT bound; Fig. 1a) was per-
formed after the addition of [3H]-NT. Thus, the −NT
assay determined the stability of the unliganded
receptor, and the +NTassay determined the stability
of the NT-bound NTS1.
Screening Ala/Leu scan mutants for
thermostability in the unliganded state
We made 340 point mutations throughout NTS1
from Ile61 to Thr400 and expressed them as maltose-
binding protein (MBP) fusions in E. coli. Three
hundred eleven positions were mutated to alanine,
and 29 native alanine residues were changed to
leucine. Western blot analyses of whole-cell lysates
probed with anti-MBP antibody showed similar
intensities of bands corresponding to the NTS1
fusion protein (within threefold of the wild-type
expression level) for all mutants, except for C142A
and C225A. These cysteine residues are predicted toform a disulfide bond, and mutating either one of
them led to a dramatic reduction in the expression
levels of the full-length fusion proteins and in-
creased proteolysis (results not shown). [3H]-NT
ligand binding assays (LBAs) performed on deter-
gent-solubilized receptors at 4 °C revealed that 50
mutants, including C142A and C225A, did not bind
an agonist possibly because the respective NTS1
mutants were misfolded or because a given muta-
tion reduced agonist affinity directly or indirectly
such that [3H]-NT binding could not be detected at
the ligand concentration used in the assay. Thermo-
stability assays were performed on each of the 290
functional mutants. The assays were performed first
in the −NTassay format to determine the stability of
unliganded detergent-solubilized NTS1 mutants.
The percentage of the remaining functional receptor
was determined by comparing the amount of bound
[3H]-NT after heating with its unheated control. As
the percentage of active wt-NTS1 remaining after
heating varied between 30% and 50%, mutant
values were scaled to values expected if the wt-
NTS1 activity remaining was 50%, thus allowing a
direct comparison between different batches of data.
The accumulated error estimated for the activity
assays, when expressed as the number of receptors
per cell, was ±15%. In summary, out of all 340 NTS1
mutants constructed, 22 (6%) showed an improve-
ment in stability (i.e., greater than 65% of functional
receptors remaining after the incubation for 30 min
at 24 °C) (Fig. 1b). In contrast, 201 mutants (59%)
266 Thermostabilization of NTS1retained a stability similar to that of wt-NTS1 in the
unliganded state (∼35% to 65% activity remaining
after heating), 67 mutants (20%) were less stable
than wt-NTS1, and 50 mutants (15%) did not bind
NT (as mentioned above). The positions of the 22
best thermostabilizing mutations of NTS1 in the
absence of ligand (Fig. 3b, blue and green) neither
conform to an obvious pattern nor correspond to the
locations of thermostabilizing mutations identified
in β1AR
19 or A2aR.
18
Most of the thermostabilized mutants retained at
least 50% of the total number of functionally
expressed receptors per cell compared to wt-NTS1
(Fig. 1b). However, we also observed exceptions.
For example, the mutation H103A stabilized the
unliganded receptor by 7–8 °C, but expression of
H103A was nearly fourfold lower than that of wt-
NTS1, making this mutant less attractive for
further use. In order to improve the expression
level, five other amino acid residues, namely,
H103N, H103S, H103V, H103L, and H103M, were
used to substitute this residue. Of these fiveFig. 3. Comparison of the unliganded-state and agonist-bo
The stability of each mutant is shown in both the unliganded
stability). Mutations combined to optimally stabilize NTS1 a
corresponds to the position of wt-NTS1. (b) The locations of 31 s
of stabilizing mutations are shown for the unliganded receptomutants, H103N and H103S expressed at the
same level as wt-NTS1, while H103V showed
only a slight improvement in expression over
H103A; all three mutations maintained the ther-
mostability conferred by H103A. In contrast,
H103L and H103M neither regained the expression
level of wt-NTS1 nor retained the thermostability
of H103A (data not shown). Although it was not
necessary to use any of these additional changes in
subsequent mutants, these data show that the low
expression level of a functional thermostable
receptor can be improved by changing the ther-
mostabilizing mutation to different amino acid
residues.
The best thermostabilizing mutations of the NTS1
unliganded state for combination into an optimally
stable receptor were chosen only after considering
their effect upon NTS1 expression. We considered
that 250 functional receptors per E. coli cell (about
25% of wt-NTS1 expression) represented the mini-
mum acceptable level of expression and, using this
as our cutoff, 19 of 22 NTS1 mutants were retainedund-state stabilities of NTS1 single Ala/Leu mutants. (a)
state (−NT stability) and the agonist-bound state (+NT
re indicated. The intersection of dotted lines in the plot
tabilizing mutations are shown in the snake plot; positions
r (blue), NT-bound receptor (red), or both (green).
Fig. 4. Denaturation profiles of the three best NTS1
single Ala/Leu mutants in the absence and in the presence
of NT. Denaturation curves of the three best thermostable
single mutants of NTS1 (A86L, H103A, and F358A) were
determined by heating the solubilized mutants at elevated
temperatures for 30 min, either in the absence of NT (a) or
in the presence of 12 nM [3H]-NT (b). The NTS1 mutants
shown are wild type (black diamonds), A86L (blue
circles), H103A (green squares), and F358A (red triangles).
(c) Table summarizing the apparent Tm values determined
by nonlinear regression of the above curves; constraint of
upper–lower boundaries was not used. The estimated
error from repeated experiments is ±2 °C. Remaining
activity was normalized to 100% based upon the amount
of binding measured in the samples incubated on ice.
267Thermostabilization of NTS1for the subsequent study. Each of these stabilizing
mutations gave an increase in the apparent Tm value
in the unliganded state of 2–10 °C, compared to wt-
NTS1 (Supplementary Table 1).
Rescreening Ala/Leu scan mutants for
thermostability in the NT-bound state
All 22 thermostabilizing Ala/Leu single mutants
selected in the unliganded state (−NT assay) were
subsequently tested for thermostability in the NT-
bound state (+NT assay). To our surprise, many of
the mutants were less stable than wt-NTS1 when
bound to NT, although they were clearly more stable
than wt-NTS1 in the unliganded state (data not
shown). In fact, 7 of the 22 mutants were less stable
in the +NT assay than wt-NTS1 (Supplementary
Table 1). Therefore, we decided to reanalyze the
mutants that retained N50% activity (i.e., at least as
stable as wt-NTS1) in the −NT assay. Thus, 137
mutants were detergent-solubilized and heated in
the presence of [3H]-NT at 37 °C for 30 min (+NT
assay; Fig. 2). Only 13 of 137 mutants screened were
found to be more stable than wt-NTS1 in the NT-
bound state (cutoff value set to ∼65%). There
appeared to be little correlation between the stability
of the mutants in the unliganded state and the
stability of the mutants in the NT-bound state (Fig.
3a), and there was no discernable pattern from the
positions of the mutations in the primary amino acid
sequence (Fig. 3b, red and green). The 13 mutants
chosen by the NT assay were, from the selection
strategy we imposed, more stable than wt-NTS1 in
the NT-bound state and at least as stable as wt-NTS1
in the unliganded state, and 11 of the 13 mutants
also expressed reasonably well (Supplementary
Table 1). Each of the stabilizing mutations had
apparent Tm values of 1–7 °C higher than that of wt-
NTS1 in the NT-bound state. Only four mutants
were more stable than wt-NTS1 in both the
unliganded state and the NT-bound state, of which
only three mutants, namely, A86L, H103A, and
F358A, were significantly more stable (Fig. 3b,
green). The denaturation profiles of these three
mutants and wt-NTS1 are shown in Fig. 4, in the
absence (Fig. 4a) and in the presence (Fig. 4b) of
bound [3H]-NT, and the apparent Tm values are
shown in Fig. 4c.
Combining mutations to further improve
receptor stability
To evolve an NTS1 mutant that was stable both in
the presence and in the absence of NT, we chose 14
single mutations that stabilized the unliganded state
(from the −NT assay) and another 13 mutations that
stabilized the NT-bound state (from the +NT assay),
including the 4 mutations that appeared in both
groups. Mutants that were significantly less stable
than wt-NTS1 in the NT-bound state (e.g., L72A)
and/or had low expression levels (e.g., D345A)
(Supplementary Table 1) were not used. Combina-
tions within subsets of mutations were obtained byPCR using random mixtures of primers, as pre-
viously described for the thermostabilization of
β1AR
19 and A2aR.
18 The most thermostable mutants
contained combinations of the five mutations A86L,
H103A, I260A, F342A, and F358A (Supplementary
Table 2). Most of these mutants also maintained
reasonably good expression levels, with many
showing improved levels of expression over wt-
NTS1. The assay conditions had to be revised at this
point by increasing the incubation temperatures (to
37 °C for the ‘−NT’ assay and to 47 °C for the ‘+NT’
assay) to ensure better differentiation in the degree
268 Thermostabilization of NTS1of stabilization between mutants. Under these
conditions, wt-NTS1 showed no binding activity,
so results were normalized to A86L, which retained
about 20% of its initial activity in both assay formats
(Fig. 5). Among the 26 mutant combinations tested,
6 combinations showed improved thermostability in
the absence of NT (score N30), and 11 combinations
showed improved thermostability in the presence of
NT (score N80) over the respective stability of A86L
(Supplementary Table 2). Mutants containing both
A86L and F358A mutations appeared to show the
best stabilization effects in both screening condi-
tions. NTS1-7a, which contains only two mutationsFig. 5. Denaturation profiles of NTS1 multiple mutants
in the absence or in the presence ofNT. Denaturation curves
of four examples of the best thermostable mutants—NTS1-
7a (A86L/F358A),NTS1-7m (A86L/I260A/F342A/F358A),
A86L, and F358A—were compared to wt-NTS1. The
solubilized receptors were heated for 30 min, either in the
absence (a) or in the presence (b) of NT: wt-NTS1 (black
diamonds), A86L (blue closed circles), F358A (red triangles),
NTS1-7a (purple inverted triangles), and NTS1-7m (green
squares). (c) Table summarizing the apparent Tm values
determined from the above curves. The estimated error
from repeated experiments is ±2 °C. Remaining activitywas
normalized to 100% based upon the amount of binding
measured in the samples incubated on ice.(A86L and F358A), gave more than 10 °C stabiliza-
tion compared to wt-NTS1 in both +NT and −NT
formats (Fig. 5). NTS1-7m (A86L, I260A, F342A, and
F358A) was found to be one of the most thermo-
stable mutants, with an apparent Tm of 50 °C in the
presence of NT (13 °C better than wt-NTS1; Fig. 5)
and an apparent Tm of 42 °C in the absence of NT
(17 °C better than wt-NTS1; Fig. 5).
Ligand binding properties of thermostable
NTS1 mutants
To define the effects of mutations on the ligand
binding properties of mutant receptors, the apparent
Kd values for agonist ([
3H]-NT) binding were
determined by saturation binding assays using
intact E. coli cells expressing wt-NTS1 or selected
mutants. Competition binding curves for the dis-
placement of [3H]-NT by the antagonist SR142948
were used to determine Ki values for its binding.
Seven mutants that showed good stabilization in
one or both +NT and −NT assays and reasonable
expressions levels were tested (Fig. 6). All the
thermostabilized NTS1 mutants had an apparent
Kd for NT binding that was either similar to that of
wt-NTS1 (Kd=0.27 nM on intact E. coli cells) or
slightly better (Fig. 6). Kd values of NT for the
mutants varied between 0.03 nM for NTS1-7o and
0.22 nM for NTS1-7l. In contrast, the affinities of
NTS1 mutants for the antagonist SR142948 varied
from near-wild-type values of 0.22 nM for NTS1-7o
to 2.8 nM for NTS1-7g when determined in
competition with [3H]-NT (Fig. 6). When the Ki
(SR146948):Kd(NT) ratio was determined, then all
the mutants tested, with the exception of NTS1-7l,
showed preferential binding to NT compared to
SR146948 by a factor of up to 18 for NTS1-7f.
Characterization of NTS1-7m
NTS1-7m satisfied our original aim of stabilizing
NTS1 in both unliganded and NT-bound states. In
addition to the thermal denaturation profiles of
detergent-solubilized NTS-7m (Fig. 5), we deter-
mined the degree of thermostabilization by measur-
ing the rate of thermal inactivation at 45 °C for
detergent-solubilized wt-NTS1 and NTS1-7m (Fig.
7a). Under the conditions used, the half-lives for
NTS1-7m were either 220 or 13.4 min, in the pre-
sence or in the absence of bound NT, respectively,
compared to values of 5.7 and 1.3 min for wt-NTS1.
Based on these half-lives, NT-bound NTS1-7m was
39-fold more stable than NT-bound wt-NTS1 and
was 10-fold more stable when the unliganded
receptors were compared.
Thermostabilization of β1AR and A2aR in DDM
resulted in both these receptors gaining stability in
short-chain detergents that are more denaturing but
more suitable for crystallization.18,19 We therefore
tested whether NTS1-7m that was thermostabilized
in DDM/Chaps/CHS showed increased stability in
other detergents that are more preferable for crystal-
lization. NTS1-7m and wt-NTS1 were solubilized in
269Thermostabilization of NTS1DDM/Chaps/CHS, bound to Ni2-affinity resin, and
washed with either DDM/Chaps/CHS (the original
detergent condition), 0.03%DDM, 0.1% n-decyl-β-D-
maltopyranoside (DM), or 0.3% n-nonyl-β-D-glyco-
pyranoside (NG). The receptors were eluted in the
desired detergents, and thermal denaturation pro-
files were determined by heating the receptors in the
presence of [3H]-NT (Fig. 7b and c). NTS1-7m was
consistently more stable than wt-NTS1 in any of the
detergents tested, with apparent Tm values that
were 7–13 °C higher than those of the wild-type
receptor. As expected, the stability of NTS1-7m
decreased as the size of the detergent micelle around
the receptor also decreased, reflecting the increasing
harshness of detergents (DDMbDMbNG) with
shorter hydrophobic chains. The amount of func-
tional receptor eluted from the Ni2-NTA column
was also consistently higher for NTS1-7m than for
wt-NTS1 [e.g., washing and eluting the receptors in
NG recovered only 3% of the functional wt-NTS1
compared to 20% for NTS1-7m (compared to values
determined in DDM/Chaps/CHS)]. Although
NTS1-7m was consistently more stable in short-
chain detergents than wt-NTS1, the degree of
stabilization was less than that observed in DDM/
Chaps/CHS (Fig. 7d).
To investigate what might contribute to the
stability of NTS1-7m, the rate of agonist dissociation
from detergent-solubilized receptors (in 0.1% DDM,
0.2% Chaps, and 0.04% CHS) was determined (Fig.
8a). In this detergent condition, the Kd values of
NTS1-7m and wt-NTS1 are 0.66 and 1.1 nM (results
not shown). Although the exact Kd values depend
on the concentrations of the detergents used, the
relative orders in the affinity of mutant NTS1s and
wt-NTS1 are unchanged. The dissociation rate of NT
from wt-NTS1 in the presence of NaCl is 50-fold
higher than that in the absence of the salt (Fig. 8a).
On the other hand, the effect of NaCl on the
dissociation rate was only ∼2-fold for NTS1-7m.Fig. 6. Agonist and antagonist binding to NTS1
mutants. (a) Saturation binding curve of a representative
[3H]−NT binding experiment with NTS1-7m in intact E.
coli cells. The Scatchard plot is shown as an inset (one-site
fit; Kd=0.34±0.03 nM). (b) Competition assays were
performed using intact E. coli cells expressing either wt-
NTS1 or NTS1mutants. Increasing quantities of antagonist
SR142948 were incubated with the cells in the presence of
5 nM agonist [3H]−NT. Competition curves for wt-NTS1
(black circles), NTS1-7a (blue triangles), andNTS1-7m (red
squares) are shown. Ki values were determined by
nonlinear regression analyses using Kd values for NT
binding determined from the saturation binding curves
(d). (c) The correlation between Kd(NT) and Ki(SR142948)
for each mutant is shown as a scatter plot, with results of a
representative experiment shown and with error bars
representing the SEM of data fitting. The red broken line
represents the Ki/Kd ratio for wt-NTS1. (d) Table summar-
izing the apparent Kd values for [
3H]−NT binding, Ki
values for SR142948, and the Ki/Kd ratio for each of the
mutants tested. Kd and Ki determinations were performed
simultaneously, in duplicate, for each mutant. SEMs are
obtained from one representative experiment and arise
from data fitting.Therefore, the off-rate of NT from wt-NTS1 was ∼8-
fold faster than that from NTS1-7m in the absence of
NaCl; however, in the presence of 0.8 M NaCl, the
off-rate of NT from wt-NTS1 was over 200-fold
faster than that from NTS1-7m (Fig. 8a).
The ability of NTS1-7m to couple to the G-protein
GαqGβ1γ1was tested in a guanosine 5′-diphosphate
(GDP)/guanosine 5′-O-[γ-thio]triphosphate
(GTPγS) exchange assay performed on receptors
expressed in insect cell membranes using the bacu-
lovirus expression system. The E. coli and insect cell
expression systems both produce NTS1with equiva-
lent NT binding activities, but the E. coli system
270 Thermostabilization of NTS1requires the presence of N-terminal and C-terminal
fusion proteins (MBP and TrxA, respectively) for
high-level expression. As TrxA at the C-terminus
could affect G-protein coupling, untagged NTS1 and
NTS1-7m were therefore expressed in insect cells for
the G-protein coupling assays. Although robust
agonist-induced nucleotide exchange at Gαq was
seen for wt-NTS1, only poor coupling was observed
for NTS1-7m (Fig. 8b).Discussion
The rat NT receptor NTS1 was an obvious target
for thermostabilization because NTS1 is not very
stable in detergent solution, especially in short-chain
detergents that are potentially useful for three-
dimensional crystallization. Heterologous expres-
sion of NTS1 in E. coli and purification of functional
receptors have been well established by White et
al.30 An essential step during the purification of
NTS1 is the use of an NT ligand-affinity column,
which allows enrichment of functional receptors.
The application of NTS1 onto the NT column
requires that no ligand is present at this time;
therefore, this dictated that NTS1 should be stabi-
lized in the unliganded state to improve its stability
during the steps before binding to the NT column.
As crystallization would likely involve the cocrys-
tallization of NTS1 with NT, it was also desirable
that stabilized NTS1 would be at least equally stable
in the presence of bound agonist as in the un-
liganded state. These two criteria governed the
approach for the stabilization procedure.
The identification and combination of thermosta-
bilizing point mutations were performed by an Ala/
Leu scanning methodology that had previously
been used to stabilize both β1AR and A2aR. Out of
the 31 best thermostabilizing point mutations
identified in NTS1 by the −NT and +NT assays,Fig. 7. NTS1-7m shows improved thermal stability and
stability in short-chain detergents compared to wt-NTS1.
(a) The rates of thermal inactivation of solubilized wt-
NTS1 (circles) and NTS1-7m (squares) in DDM/Chaps/
CHSwere compared by heating the samples at 45 °C either
in the presence (red lines) or in the absence (black lines) of
[3H]−NT. Half-lives were determined from the curves by
nonlinear regression of the single-exponential curve after
constraining the values for Y=0–100% and plateau=0%:
unliganded wt-NTS1, 1.3 min; NT-bound wt-NTS1,
5.7 min; unliganded NTS1-7m, 13.4 min; NT-bound
NTS1-7m, 220 min. (b–d) Thermostability of wt-NTS1
and NTS1-7m in various detergents. Receptors were
solubilized in DDM/Chaps/CHS, bound to Ni2-NTA
beads, and then washed and eluted with a buffer contain-
ing either DDM/Chaps/CHS (black circles), 0.03% DDM
(red squares), 0.1%DM (blue triangles), or 0.3%NG (green
diamonds). Thermostability assays were performed in the
presence of NT (b: wt-NTS1; c: NTS1-7m). Remaining
activity was normalized against the unheated control in
each detergent condition (100%), although recovery yields
were different in each case (see the main text). The
apparent Tm values (d) were determined from the curves
by nonlinear regression.the combination of the four mutations A86L, I260A,
F342A, and F358A produced one of the most
thermostable mutants developed so far, NTS1-7m.
NTS1-7m displayed several modified properties
compared to wt-NTS1, including the following: an
increase in the thermostabilities of the solubilized
unpurified form (Fig. 5) and the partially purified
form, as well as an increase in thermostability in
short-chain detergents (Fig. 7); a decrease in the NT
dissociation rate (yet similar apparent NT affinity)
and a smaller effect of Na+-induced NT dissociation
(Fig. 8a); a decrease in antagonist affinity (Fig. 6);
and reduced ability to functionally couple to Gαq
Fig. 8. Rate of dissociation of NT and activation of G-
protein by wt-NTS1 and NTS1-7m. (a) The dissociation
rates of [3H]-NT from wt-NTS1 (circles) and NTS1-7m
(squares) were determined by quantifying the amount of
[3H]-NT remaining bound to the receptors (total NT
concentration in the assay, 2 nM) upon addition of 50 μM
unlabeled NTon ice in the presence (red) or in the absence
(black) of NaCl. The rate of [3H]-NT dissociation was
determined by nonlinear regression with single-exponen-
tial decay. (b) Recombinant receptors in urea-washed
insect cell membranes were tested for their ability to
stimulate G-protein using a GDP/[35S]−GTPγS exchange
assay. All assays contained purified recombinant Gαq
Gβ1γ1, [
35S]−GTPγS, and insect cell membranes contain-
ing either wt-NTS1 or NTS1-7m. Receptors were incu-
bated with no additional ligands (blue bars), with NT
(grey bars), or with the antagonist SR48692 (green bars).
The amount of [35S]−GTPγS bound to the G-protein
complex was determined as described in the text.
271Thermostabilization of NTS1Gβ1γ1 (Fig. 8b). While it would be convenient to
associate each of these properties with a single
mutation within the receptor, it is likely that the
combined effect of all the four mutations in NTS1-
7m generates the overall characteristics of the
mutant. For the purposes of this discussion, how-
ever, each property of NTS1-7m will be discussed in
terms of how individual and/or combined muta-
tions within NTS1-7m may contribute to its
observed characteristics.
Several three-dimensional structural models were
made by overlaying the position of NTS1 amino acid
primary sequence to bovine rhodopsin and β1AR-
m23 crystal structures according to amino acid
sequence alignment (Fig. 9, shown in the β1AR-m23 structure). The residue A86 is located in TM1;
the equivalent amino acid side chains in the
structures of β2AR (I55),
12 β1AR (I63),
15 rhodopsin
(L59),8,9 and A2aR (C28)
14 all make contact with the
lipid environment, but also with TM2. Based on the
above receptor structures, the I260 side chain in TM5
is predicted to point towards the (D/E)RY motif in
TM3. F342 is located in extracellular loop 3 (ECL3)
and is likely to be able to interact with residues
known to form the ligand-binding pocket. F358 is in
TM7 and may interact with a conserved tryptophan
residue in TM6 (position 6.4836) that is thought to be
part of the “toggle switch” for receptor activation.37
Binding of NT is clearly one of the important
factors governing the stability of NTS1, even for the
wild-type receptor. NT binding to the thermostable
mutant NTS1-7m differed in several ways from
binding to wt-NTS1, although the Kd values for
binding were similar. The rate of dissociation of NT
from NTS1-7m was 8-fold slower than that for wt-
NTS1. However, the rate of NT dissociation was
only affected by about 2-fold by the presence of
0.8 M NaCl, compared to an acceleration of
dissociation by over 50-fold for wt-NTS1. In
contrast, the affinity of the antagonist SR142948 for
NTS1-7m was reduced by ∼4-fold. The binding site
for NT was predicted to include the region of
ECL3;27,38,39 thus, the F342A mutation of NTS1-7m
may be of importance in regard to its modified
agonist-binding properties. While F342 has not
previously been reported as being directly involved
in NT binding, the ECL3 location of F342 places it
within the region of the predicted receptor-agonist-
binding pocket, and modeling studies have impli-
cated F342 in NT binding through its contribution to
the aromatic character of the ligand-binding pocket.39
The binding of antagonists to NTS1-7m was
consistently weaker compared to binding to wt-
NTS1, whether it was measured as a Ki value from
competition binding experiments between SR142948
and [3H]-NT (4-fold weaker binding; Fig. 6) or by a
saturation binding assay using [3H]−SR48692 (15-
fold weaker binding; data not shown). A reduced
affinity of antagonist binding has been previously
observed for F358A-mutated NTS1.40 Mutational
studies, combined with binding assays using
SR48692 and its analogues, have predicted π–π
interactions between the dimethoxyphenyl group of
the ligand and F358 of the receptor. SR48692 has
additional predicted contacts at M208, F331, R327,
Y324, Y351, T354, and Y359 of the receptor, none of
which is mutated in NTS1-7m.
In addition to the observed decrease in the NT off-
rate, binding of NT to NTS1-7m was also not
modulated by Na+ similarly to wt-NTS1 (Fig. 8a).
Like other rhodopsin-like GPCRs, NTS1's affinity
for its agonist is influenced by the presence of Na+,
with a decrease in the apparent NT affinity being
observed with increasing Na+ concentration.34 The
Na+ effect can be eliminated by the mutation of a
highly conserved aspartic acid residue in TM2 to an
uncharged residue (D113A).34 The equivalent resi-
due D83 in bovine rhodopsin, for example, is
Fig. 9. Positions of thermostabi-
lizing mutations in NTS1-7m. The
structure of the β1AR (PDB ID
2VT4) is shown in rainbow colors
(N-terminus in blue; C-terminus in
red), with the bound antagonist
cyanopindolol shown as a space-
filling model. The equivalent posi-
tions (via primary amino acid
sequence alignment) of five thermo-
stabilizing mutations of NTS1 are
shown, with side chains as space-
filling models (black) and with
labels corresponding to the amino
acid residues in NTS1.
272 Thermostabilization of NTS1involved in an extensive H-bond network that has
been suggested to contribute to the stability and
function of this receptor.9 How the Na+ effect has
been largely abolished by mutations in NTS1-7m,
none of which lie in TM2, remains unclear, nor is it
obvious whether the Na+ effect observed with
NTS1-7m relates to the Na+ effect involving D113.
While our primary purpose was to thermostabi-
lize the receptor in various detergents, it is interest-
ing to determine whether the mutant NTS1-7m
could assume the activated (R∗) conformation to
couple to G-proteins, either in the absence or in the
presence of NT. To our surprise, NTS1-7m did not
efficiently catalyze nucleotide exchange at Gαq (Fig.
8b), either in the absence or in the presence of NT,
even though NT could clearly bind to the receptor.
This was unexpected because one of the thermo-
stabilizing mutations was F358A, which has been
previously shown to promote constitutive activity of
NTS1,41 so our expectation was to observe some
constitutive activity of NTS1-7m in addition to
agonist-induced G-protein coupling activity. Dis-
ruption of the intrahelical salt bridge (“ionic lock”)
of the conserved (D/E)RY motif in TM3 is important
for GPCR activation, and mutations within this
motif have been associated with the constitutive
activity of GPCRs.24,42 In this regard, the I260A
mutation, in combination with the F358A mutation,of NTR1-7m may be playing a part. Sequence
alignment36 of rat NTS1 with turkey β1AR, human
β2AR, human A2aR, and bovine rhodopsin places
I260 of NTR1 at V230 (β1AR), V222 (β2AR), I200
(A2aR), and L226 (rhodopsin). These hydrophobic
side chains point towards the main-chain atoms of
the (D/E)RY tyrosine in the crystal structures of
these receptors [Protein Data Bank (PDB) IDs 2VT4,
2RH1, 3EML, and 1GZM]. It may be that removal of
the isoleucine side chain in the NTS1 mutation
I260A in some way counteracts the expected
constitutively activating effect of the F358A muta-
tion, as well as the ability to assume agonist-induced
activated conformations.
The four mutations in NTS1-7m clearly have had
an effect on the global conformation of the receptor.
This is evident from the improved thermostability of
NTS1-7m and the inability of NT-boundNTS1-7m to
couple to G-proteins efficiently. Only one of the four
thermostabilizing mutations could possibly interact
with NT based upon current models, suggesting that
the other three mutations in combination affect the
pharmacology of NTS1-7m through indirect effects.
In the absence of a crystal structure, we cannot
definitively say what conformation NTS1-7m has;
however, given the G-protein coupling data, when
NT is bound, it is not an activated state of the
receptor.
273Thermostabilization of NTS1One aim of producing NTS1-7m was to provide a
mutant that is suitable for purification by the
sequential use of Ni2-NTA resin and an NTcolumn30
and that is more stable than wt-NTS1. While the
stability of solubilized NTS1-7m was improved
compared to that of wt-NTS1 (i.e., beneficial during
the initial step of receptor purification), the use of
the NT column was not successful. This is largely
because the off-rate of NT from NTS1-7m in the
presence of high NaCl concentrations is consider-
ably slower than that for wt-NTS1. NTS1-7m binds
to an NT column, but it cannot be eluted using high-
concentration (e.g., 1 M) NaCl; therefore, the NT
column step in its present form is no longer an
effective tool for purification. If we were to continue
using the established purification procedures,
further work on mutagenesis efforts to stabilize
NTS1 with different sets of mutations will be
required. Otherwise, a new purification scheme
would need to be developed before crystallization
can be attempted with NTS1-7m.
Recently, a study by Sarkar et al. describing the
evolution of NTS1 for expression and stability was
published.43 This approach was based on random
mutagenesis by error-prone PCR, expression of the
mutant library in E. coli, and identification of the
most highly expressing mutants by a fluorescence-
activated cell sorter after binding a fluorescent NT
analogue. This procedure identified the mutant D03,
which contains nine mutations (H103D, H105Y,
A161V, R167L, R213L, V234L, H305R, S362A, and
S417C) located in TM2, TM3, ECL2, TM6, TM7, and
the C-terminus. The NTS1 mutant D03 expressed
almost 10-fold better in E. coli than wt-NTS1, and it
appeared 3- to 4-fold more stable than wt-NTS1 in
detergent at 45 °C (based on replotting of the data in
Fig. 5 of Sarkar et al.43). This work assumed that
there was a correlation between expression levels
and stability, but mutagenesis work on the β1AR,
19
A2aR,
18 and NTS1 reported here (Fig. 1) shows that
stability and expression levels are only weakly
correlated. Because of this, our approach to selecting
the best receptor construct was based on choosing
the most stable mutants regardless of their expres-
sion levels. Indeed, we found NTS1-7m to be 10-fold
more stable at 45 °C in detergent solution (in the
absence of NT; Fig. 7), with an expression level (less
than 2-fold improvement) similar to that of wt-
NTS1. In addition, this stabilization effect was
achieved by having only four mutations in NTS1-
7m compared with nine mutations (excluding silent
mutations) in the mutant D03. The most stabilizing
conditions that we observed for NTS1-7m were in
the presence of bound NT; under these conditions,
NTS1-7m was 39-fold more stable than wt-NTS1,
but equivalent figures for the mutant D03 are not
available. One interesting finding in the mutant D03
was that its NT binding is also insensitive to Na+
concentration. Unlike NTS1-7m, however, D03 does
contain mutations in TM2 near D113, as well as
residues in TM3, which may be in contact with
D113. Again, without a crystal structure, it is
difficult to suggest how this effect has arisen.We have now successfully applied the approach of
conformational thermostabilization to three GPCRs:
NTS1 (this work), A2aR,
18 and β1AR.
19 In all cases,
the receptor is stabilized in a conformation that
preferentially binds either agonist or antagonist,
depending upon which ligand was used during the
selection procedure. Currently, there are insufficient
data to predict which mutation may be thermo-
stabilizing, so an Ala/Leu scan coupled to thermo-
stability assays is still the best way to proceed. Our
data also show that the position of thermostabilizing
mutations is different for each receptor, so it is likely
that the transferability of thermostability between
distantly related receptors is low. After producing
the thermostabilized β1AR mutant, the structure
containing bound antagonist was determined to
2.7 Å resolution.15 The intrinsic instability of agonist-
bound wt-NTS1 compared to antagonist-bound wt-
β1AR suggested thatmore effort is needed to achieve
an optimally stabilized NT receptor that is suitable
for crystallization. Our work presented here shows
that a systematic mutagenesis approach can be used
to evolve a receptor that is thermostable both in the
presence and in the absence of ligand. In addition,
this selection strategy gave rise to mutant receptors
that bind the agonist NT preferentially over antago-
nist SR142948, although the combination of two
selection pressures on stability has resulted in a
mutant receptor that virtually does not couple to G-
proteins. A different approach will be required to
stabilize the receptor in a fully activated state, which
may require the selection of thermostable mutants in
the presence of relevant G-proteins.Materials and Methods
Materials
The tritiated agonist [3H]-NT was purchased from
Perkin Elmer. The tritiated antagonist [methoxy-3H]
−SR48692 {SR48692: {2-[(1-(7-chloro-4-quinolinyl)-5-(2,6-
dimethoxyphenyl)pyrazol-3-yl)carbonylamino]tricyclo
(3.3.1.1.3.7)decan-2-carboxylic acid}} was purchased from
Amersham Biosciences/GE Healthcare (discontinued in
November 2007). Unlabeled NT was purchased from
Sigma. The unlabeled antagonist SR142948 {2-[[[5-(2,6-
dimethoxyphenyl)-1-[4-[[[3-(dimethylamino)propyl]
methylamino]carbonyl]-2-(1-methylethyl)phenyl]-1H-
pyrazol-3-yl]carbonyl]amino]-tricyclo[3.3.1.13.7]decan-2-
carboxylic acid} was purchased from Tocris Bioscience
(referred to as SR142948A in Gully et al.44). Detergents
were purchased from the following suppliers: DDM
(Glycon or Anatrace), DM (Anatrace), NG (Anatrace),
Chaps (Anatrace), and CHS Tris salt (Sigma or Anatrace).
Detergent concentrations are given as percent weight per
volume (g/100 ml solution).NTS1 constructs for expression in E. coli
and insect cells
wt-NTS1 refers to the N-terminally truncated rat NT
type I receptor starting at Thr43. The wild-type receptor or
a mutant form of receptor was expressed in E. coli as a
274 Thermostabilization of NTS1fusion protein, with the E. coliMBP preceding the receptor
N-terminus and a thioredoxin–decahistidine tag (TrxA-
H10) following the receptor C-terminus.
30,45 For the
construction of recombinant baculoviruses, the cDNA
sequences for wt-NTS1 and NTS1-7m were subcloned into
the baculovirus transfer vector pFastBac1 (Invitrogen)
without coding for the fusion partners at the N-terminus
or C-terminus (Met-NTS1T43-Y424).
Site-directed mutagenesis
Three hundred forty mutations were introduced
throughout NTS1 from amino acid residues Ile61 to
Thr400, spanning all seven TM helices, the putative helix
8, three intracellular and three extracellular loops, and the
proximal half of the C-terminus, including potential
phosphorylation sites. Each amino acid residue was
changed to alanine, unless it was already an alanine in
the wt-NTS1 sequence, at which time it was changed to
leucine. Mutants were created by PCR-based site-directed
mutagenesis using the E. coli expression plasmid as
template and following the QuikChangeII methodology
(Stratagene) but using KOD hot start polymerase (Nova-
gen). The positions of helices were predicted by aligning
the amino acid sequence of rNTS1 with those of three
other type 1 GPCRs (bovine opsin, turkey β1AR, and
human A2aR) and by superposing the alignment onto the
known crystal structure of bovine rhodopsin (PDB ID
1GZM).9 Individual clones were fully sequenced in the
NTS1 coding region to ensure that only the desired
mutation was present. Multiple mutations were intro-
duced to the receptor by including up to four pairs (five
pairs only in one case) of mutagenesis primers in a PCR,
using a template already containing one mutation.
Expression of NTS1 in E. coli for screening of mutants
Expression of wt-NTS1 and NTS1 mutants was per-
formed in E. coli,30 with modifications. Cultures were
grown in 50 ml of 2× TY supplemented with 100 μg/ml
ampicillin and 0.2% glucose in 250-ml Erlenmayer flasks at
37 °C, with shaking to an OD600 of 0.5. After the addition
of 0.5 mM IPTG, the temperature was lowered to 22 °C,
and the cultures were incubated with shaking for another
24 h. Cultures were harvested as 2-ml aliquots by
centrifugation at 13,000g for 1 min, flash-frozen in liquid
nitrogen, and stored at −20 °C.
Radioligand binding and thermostability assays
Agonist binding to detergent-solubilized receptors was
performed with [3H]-NT.30 The harvested E. coli cells
expressing wt-NTS1 or mutant NTS1 were suspended in
lysis buffer [50 mM Tris·HCl (pH 7.4), 200 mM NaCl, and
30% (vol/vol) glycerol] and supplemented with protease
inhibitor cocktail (Roche), 0.75mg/ml lysozyme, 25 μg/ml
DNase I, 6.25 mM MgCl2, 0.1% bovine serum albumin
(BSA), and 0.004% bacitracin. Receptors were solubilized
by adding 1% DDM, 0.6% Chaps, and 0.12% CHS (final
volume, 500 μl). After centrifugation, the cleared lysate
was used directly in LBAs in the assay buffer [50 mM
Tris·HCl (pH 7.4), 1 mM ethylenediaminetetraacetic acid
(EDTA), 0.1% BSA, 0.004% bacitracin, and 30% glycerol]
containing detergents (0.22% DDM, 0.6% Chaps, and
0.12% CHS; final concentrations after addition of lysate)
and 12 nM [3H]-NT. The total number of functional
receptors was determined by incubating the receptor inthe assay buffer at 4 °C for 1 h in the presence of [3H]-NT
(‘normal’ LBA). Nonspecific binding of [3H]-NT was
assessed by either determining [3H]-NT binding to wt-
NTS1 in the presence of 4 μM unlabeled NT and/or
performing LBA using DH5α cells not expressing any
receptors in the presence or in the absence of 4 μM
unlabeled NT. The amount of functional wt-NTS1 or
mutant NTS1 (i.e., receptors retaining ligand binding) was
determined by a ‘spin assay.’ A receptor–ligand complex
was separated from free radioligand by applying the assay
mixture on a spin column (QS-QMminicolumns, formerly
supplied by Perkin Elmer and presently supplied by Fisher
Scientific) packed with Sephadex G50 (GE Healthcare)
preequilibrated in 50 mM Tris·HCl (pH 7.4), 1 mM EDTA,
and 0.1% DDM. The receptor–ligand complex was eluted
by centrifugation and analyzed by liquid scintillation
counting (Beckman LS 6000).
Thermal stability was determined in the absence (‘−NT’
assay) or in the presence (‘+NT’ assay) of [3H]-NT. In the
−NT assay, neither 3H-labeled nor unlabeled NT was
present during incubation at 24 °C for 30 min. Samples
were cooled on ice for 5 min, and then ligand was added
([3H]-NT or [3H]-NT/unlabeled NT), and the samples
were incubated for an additional hour on ice. The amount
of functional receptors after heating was determined by
spin assay, as described above. In the +NT assay, the 30-
min incubation at 37 °C was performed in the presence of
[3H]-NT or [3H]-NT/unlabeled NT. Samples were cooled
on ice then incubated on ice in the cold room for an
additional hour before spin assay.
Saturation binding experiments were performed in the
presence of 0.15–20 nM [3H]-NTusing detergent-solubilized
receptors in LBA buffer. Nonspecific binding of NT to the
receptor was determined by including 4 μM unlabeled NT.
The apparent Kd values were obtained by nonlinear regres-
sion analysis using a one-site saturation binding with a
ligand depletion model in Prism software (GraphPad).
Thermal denaturation curves were constructed by
incubating solubilized receptors in the assay buffer in
the absence (−NT) or in the presence (+NT) of 12 nM [3H]
−NT at eight different temperatures between 0 and 70 °C
for 30 min. The samples were cooled on ice, and ligand
was added to ‘−NT’ assay mixtures. All the samples were
subjected to spin assay after the 1-h incubation on ice. A
potential change in nonspecific binding upon heating at
extreme temperatures was initially tested by carrying out
thermal denaturation experiments, including 4 μM unla-
beled NT in the assays; no changes in nonspecific binding
were seen after incubation at high temperatures. Data
were analyzed by nonlinear regression using a Boltzmann
sigmoidal model in the Prism software.Denaturation time course of NTS1
To compare the stability of wt-NTS1 and mutant NTS1,
the rate of thermal inactivation was tested by the decrease
in activity over a period of time. NTS1 fusion proteins
were solubilized, and +/−NT assays were prepared (as in
thermostability assays) in large batches. Assay mixtures
were aliquoted into eight equal amounts (∼130 μl/tube)
and heated at 45 °C in the presence or in the absence of
[3H]-NT. One tube was taken out of the incubator at eight
different time points—0 (no incubation at 45 °C), 5, 10, 20,
30, 45, 60, and 120min for −NTassays, and 0, 15, 30, 45, 60,
90, 120, and 180 min for NTassays and was plunge-cooled
on ice for 5–10 min. The tritiated ligand [3H]-NT was
added to −NT assay samples. Samples were then
incubated on ice for an additional hour before spin
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120 min (−NT) and for 0 and 180 min (+NT) at 45 °C in the
presence of 4 μM unlabeled NT. No changes were
observed in nonspecific binding after a long incubation.
Data were analyzed by nonlinear regression using a one-
phase exponential decay model in Prism software.
LBAs using intact E. coli cells
The frozen aliquots of cells expressing wt-NTS1 or
mutant NTS1 were thawed on ice and resuspended in 1 ml
of cold TEBB buffer [50 mM Tris·HCl (pH 7.4), 1 mM
EDTA supplemented with 0.1% (wt/vol) BSA, and 0.004%
bacitracin]. A 50-μl aliquot of cell mixture was used in a
total volume of 500 μl of assay mixture (TEBB buffer and
no detergents) containing 1 pM to 10 nM [3H]-NT.
Nonspecific binding of radioligand to the receptor was
determined by including 4 μM unlabeled NT. The assay
mixtures were incubated on ice for 2 h, and then applied to
GF/B glass-fiber filters (Whatman) pretreated with poly-
ethylenimine. The filters were washed three times with
ice-cold TE (50 mM Tris, 1 mM EDTA, pH 7.4) buffer,
dried, and counted in a Beckman LS 6000 scintillation
counter. The apparent Kd values were obtained by
nonlinear regression analysis using a one-site saturation
binding with a ligand depletion model in Prism software.
The binding of the antagonist SR142948 to wt-NTS1 and
mutant NTS1 was determined using the unlabeled anta-
gonist SR142948 in a competition assay format. LBAs on
intact E. coli cells were carried out at the [3H]-NT
concentration of 5 nM in the presence of 10 pM to 10 μM
unlabeled antagonist. Assay samples were incubated on
ice for 2 h, then the mixture was applied to GF/B filters as
described above. Saturation binding experiments of the
same NTS1 samples were carried out in parallel to
determine the apparent Kd values. The apparent Ki values
were determined by nonlinear regression analysis using a
one-site competition model in Prism software.
Small-scale partial purification of NTS1 for stability
tests in different detergents
The pellet from 100 ml of E. coli culture, expressing wt-
NTS1 or mutant NTS1, was solubilized in 6 ml of lysis
buffer [50 mM Tris·HCl (pH 7.4), 200 mM NaCl, and 30%
(vol/vol) glycerol] containing 1% DDM, 0.6% Chaps, and
0.12% CHS. Five hundred microliters (50:50 slurry) of Ni2-
NTA agarose (Qiagen) pretreated with binding buffer
[50 mM Tris·HCl (pH 7.4), 30% (vol/vol) glycerol, 50 mM
imidazole, 100 mM NaCl, 0.1% DDM, 0.6% Chaps, and
0.12% CHS] was incubated with 1 ml of cleared lysate in
the cold room with constant mixing for 1 h. The resin was
washed once with 1 ml of binding buffer, then washed
twice with 1 ml of wash buffer [50 mM Tris·HCl (pH 7.4),
30% (vol/vol) glycerol, 50 mM imidazole, 100 mM NaCl,
and one of the desired detergents or the detergent
combination (0.1% DDM/0.6% Chaps/0.12% CHS, 0.03%
DDM, 0.1% DM, or 0.3% NG)]. The receptor was eluted
from Ni2-NTA resin using an elution buffer [50 mM
Tris·HCl (pH 7.4), 30% (vol/vol) glycerol, 200 mM
imidazole, 100mMNaCl, and one of the desired detergents
or the detergent combination]. Samples were subjected to
spin assays. Thermostability was determined from dena-
turation profiles of the receptors in the desired detergent.
Dissociation of NT from detergent-solubilized NTS1
NTS1 fusion proteins were solubilized in a volume of
25 ml containing 5 g of wet E. coli cell paste, as describedpreviously.30 Receptors (0.7–0.8 nM) were incubated on ice
for 2 h with [3H]-NT (2 nM) in assay buffer [50 mM
Tris·HCl (pH 7.4), 1 mM EDTA, 0.1% BSA, and 0.004%
bacitracin] containing detergent (0.1% DDM, 0.2% Chaps,
and 0.04% CHS). [3H]-NT dissociation was then initiated
by addition of 50 μM unlabeled NT or by addition of
50 μMNT and NaCl (833 mM). Samples were subjected to
spin assays using Bio-Spin 30 Tris columns (Bio-Rad)30
after the following incubation times: 0.1, 0.5, 1, 2, 3, 4, 5,
and 22 h for wt-NTS1 (with and without NaCl), and after
additional time points, 25 and 29 h, for NTS1-7m (with
and without NaCl). The data were analyzed by nonlinear
regression analysis using a one-phase exponential decay
model in Prism software.
Expression of NTS1 in insect cells and preparation
of P2 membranes
N-terminally truncated receptors (Met-NTS1T43-Y424)
(see NTS1 Constructs for Expression in E. coli and Insect
Cells) were produced in Trichoplusia ni insect cells using
the baculovirus expression system. Insect cells were
infected at a multiplicity of infection of 5 and incubated
for 48 h at 21 °C before harvest.
NTS1-enriched membranes were obtained as a P2
fraction from the insect cells essentially as described,46
using a solution of 10 mM Mops (pH 7.5), 5 mM ethylene
glycol bis(b-aminoethyl ether) N,N′-tetraacetic acid, and
100 μM 4-(2-aminoethyl)benzenesulfonyl fluoride HCl as
lysis buffer. The P2 membranes were resuspended in lysis
buffer containing 12% (wt/wt) sucrose, snap-frozen in
liquid nitrogen, and stored at −80 °C.
Prior to G-protein coupling assays, the P2 membranes
were treated with urea to remove peripherally bound
membrane proteins.47,48 The urea-stripped membranes
were resuspended in 12% (wt/wt) sucrose containing
Mops buffer (10 mM, pH 7.5), snap-frozen in liquid
nitrogen, and stored at −80 °C. The receptor density in
urea-washed P2 membranes was determined by [3H]
−NT saturation binding analysis. The samples were
incubated for 1 h on ice in 0.5 ml of assay buffer [50 mM
Tris·HCl (pH 7.4), 1 mM EDTA, 0.1% BSA, and 0.004%
bacitracin]. Nonspecific [3H]−NT binding was deter-
mined in the presence of 2 μM unlabeled NT. Separation
of bound ligand from free ligand was achieved by rapid
filtration through GF/B glass-fiber filters pretreated with
polyethylenimine.GDP/GTPγS exchange assay
Cephalopod Gαq was purified from dark-adapted
retinas of Sepia officinalis, as described previously.47 The
dimer complex of Gβ1 and Gγ1 was purified from bovine
retina.49 The receptor-catalyzed exchange of GDP for
GTPγS on Gαq was determined by modification of
previously described procedures.46,48 Reactions were
carried out in 12 mm×75 mm siliconized borosilicate
glass test tubes in a total assay volume of 50 μl. Urea-
washed insect cell membranes containing wt-NTS1 or
NTS1-7m were added to G-protein (Gαq Gβ1γ1) on ice to
give a total volume of 30 μl. A reaction contained either the
agonist NT or the nonpeptide antagonist SR48692,50 or
neither. GDP/GTPγS exchange was initiated by the
addition of a 20-μl solution of [35S]−GTPγS (Perkin
Elmer). The final concentrations of the components in
each reactionwere as follows: 50mMMops (pH 7.5), 1mM
EDTA, 100mMNaCl, 1mMDTT, 3mMMgSO4, 0.3% BSA,
1 μM GDP, 4 nM [35S]−GTPγS, 40 μM AppNHp, 0.4 mM
276 Thermostabilization of NTS1CMP, 1 nM receptor, 100 nM Gαq, 500 nM Gβ1γ1, and
either 10 μMNT, 40 μMSR48692, or no ligand. The reaction
mixtures were incubated at 30 °C for 5min. Reactions were
terminated by addition of 2 ml of ice-cold stop buffer
[20 mM Tris·HCl (pH 8.0), 100 mM NaCl, and 25 mM
MgCl2]. The entire volume of each samplewas filtered over
a nitrocellulose membrane on a vacuum manifold. Filters
were then washed six times with 2 ml of ice-cold stop
buffer. The nitrocellulose membranes were dried over-
night, and radioactivity was quantified by liquid scintilla-
tion in a Beckman LS 6500 scintillation counter.Acknowledgements
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